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Abstract
One mechanism frequently utilized by tumor cells to escape immune system recognition and elimination is suppression of
cell surface expression of Major Histocompatibility Class II (MHC II) molecules. Expression of MHC II is regulated primarily at
the level of transcription by the Class II Transactivator, CIITA, and decreased CIITA expression is observed in multiple tumor
types. We investigate here contributions of epigenetic modifications to transcriptional silencing of CIITA in variants of the
human breast cancer cell line MDA MB 435. Significant increases in histone H3 lysine 27 trimethylation upon IFN-c
stimulation correlate with reductions in transcription factor recruitment to the interferon-c inducible CIITA promoter,
CIITApIV, and with significantly increased CIITApIV occupancy by the histone methyltransferase enhancer of zeste homolog
2 (EZH2). Most compelling is evidence that decreased expression of EZH2 in MDA MB 435 variants results in significant
increases in CIITA and HLA-DRA mRNA expression, even in the absence of interferon-c stimulation, as well as increased cell
surface expression of MHC II. Together, these data add mechanistic insight to prior observations of increased EZH2
expression and decreased CIITA expression in multiple tumor types.
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Introduction
Major histocompatibility class II (MHC II) genes encode cell
surface proteins responsible for presenting extracellularly derived
peptides for activation of CD4
+ T cells. As activated T cells are in
turn responsible for driving adaptive immune responses, MHC II
molecules play critical roles in regulating immune recognition of
pathogens and tumors. Constitutive expression of MHC class II is
limited to professional antigen presenting cells, but MHC II
expression is induced in all nucleated cells by inflammatory
cytokines, of which IFN-c is the most potent [1,2]. Although CD8
+
T cells are directly responsible for lysis of infected cells and tumor
cells, recent studies have shown that peptide immunization in the
presence of CD4
+ T cells enhances CD8
+ T cell responses [3].
Further, several murine tumor models have demonstrated that
CD4
+ T cells are required for an effective anti-tumor immune
response [4,5,6,7]. Loss of MHC II expression is associated with
decreased numbers of tumor infiltrating T cells and with increased
tumor aggressiveness [8,9]. Together, these observations suggest
CD4
+ T cells respond to tumor antigens presented via MHC II to
induce an effective immune response and emphasize the
importance of transcriptional regulation of MHC II genes in
cancer cells.
Tight regulation of MHC II transcription is necessary for
proper initiation, stabilization, and termination of adaptive
immune responses to infection and to tumors. MHC II genes
are regulated by a multi-protein enhanceosome complex that
binds the W-X-Y region of HLA-DRA promoters, assembly of
which is stabilized by the Class II transactivator, CIITA [10,11].
While CIITA does not directly bind MHC II promoters, its
association with the pre-assembled enhanceosome complex is
required for MHC II expression and serves to coordinate steps
leading to transcriptional initiation [12,13]. CIITA recruits to
MHC II promoters, including the HLA-DRA proximal promoter
utilized in this study, components of the basal transcriptional
machinery, histone acetyltransferases (HATs), histone deacetylases
(HDACs), chromatin remodeling complexes, and kinases that
phosphorylate RNA pol II [14,15,16,17,18,19].
CIITA transcription is also tightly regulated in a cell specific
manner from four distinct promoters [20,21]. Promoter I drives
expression of CIITA in dendritic cells [22], the function of
promoter II is unknown, and promoter III drives constitutive
CIITA expression in B cells but can also be up regulated with
cytokine stimulation [23,24,25]. Transcription of CIITA in non-
antigen presenting cells is induced by IFN-c by orchestrated
binding of multiple transcription factors to the promoter IV
isoform of CIITA (CIITApIV) [24]. Transcriptional activation of
CIITApIV by IFN-c requires the assembly of interferon regulatory
factor 1 (IRF-1), signal transducer and activator of transcription 1
(STAT-1), and ubiquitous factor 1 (USF-1) [26]. STAT-1 directly
binds ubiquitously expressed USF-1 at the E-box of the IFN-c
activated sequence (GAS). STAT-1 also initiates transcription
from the IRF-1 promoter; once IRF-1 is expressed, it subsequently
binds the IFN response element (IRE) site at CIITApIV [25].
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modifications to chromatin play important roles in regulating
transcription of HLA-DRA and CIITApIV genes [27,28,29]. In
unstimulated cells, the HLA-DRA promoter exhibits low basal
acetylation which allows for binding of the ubiquitously expressed
components of the enhanceosome complex. Following cytokine
stimulation, acetylation of histones (H) H3 and H4 significantly
increases, allowing recruitment of CIITA and the basal transcrip-
tion machinery and initiation of MHC II transcription [15,30].
CIITApIV is also regulated by multiple epigenetic modifications
and is characterized as a bivalent promoter with both activating
and repressing chromatin marks. In unstimulated cells, CIITApIV
exhibits elevated trimethylation of histone H3 lysine 27
(H3K27me3) and low acetylation of histones H3 and H4. In the
presence of IFN-c, changes in higher order chromatin structure
are followed by increases in acetylation of histones H3 and H4
[31,32], increased trimethylation of histone H3 lysine 4
(H3K4me3) [33], and a significant and rapid decrease in
H3K27me3 [32,34,35]. The histone methyltransferase (HMTase)
largely responsible for the addition of methyl groups to H3K27 is
the Enhancer of Zeste Homolog 2 (EZH2) [36,37], the catalytic
subunit of the Polycomb repressive complex 2 (PRC2) which is
involved in maintaining epigenetic memory and transcriptional
silencing [36,38]. While EZH2 has previously been shown to bind
CIITApIV in malignant uveal melanoma cells, mechanistic roles
for EZH2 in regulating CIITA and MHC II expression remain to
be elucidated. Indeed, although studies have demonstrated that
EZH2 is frequently overexpressed in a wide variety of cancers
including tumors of the prostate and breast, mechanistic links of
EZH2 to cancer progression remain areas of intense investigation.
Decreased expression of MHC II has been previously described
in breast tumors [9,39]. Variants of the MDA MB 435 human
breast cancer cell line differ in their metastatic ability [40] and
have recently been classified as members of the HER-2
overexpressing subtype of breast carcinoma [41]. Previous work
has demonstrated that among these variant lines, 435 Brain 1 cells
exhibit poor metastatic ability while 435 Lung 2 cells exhibit high
metastatic ability [40,42]. We provide additional evidence for
epigenetic regulation of CIITA linked to the decreased expression
of cell surface MHC II in highly metastatic breast cancer cells. In
this study, we analyzed MHC II and CIITA expression patterns in
variants of MDA MB 435. Initial studies determined a loss of cell
surface MHC II in the MDA MB 435 variants which correlated
with increased metastatic potential, decreased CIITA expression,
and suppression of CIITApIV. We provide evidence that in the
MDA MB 435 variants, CIITApIV maintains a closed chromatin
conformation in the presence or absence of IFN-c stimulation.
Elevated levels of EZH2 at CIITApIV and the resulting increases
in CIITApIV H3K27me3 occur in the presence of IFN-c and
leave the proximal promoter inaccessible for transcription factor
binding or transcription initiation. Decreased expression of EZH2
results in expression of CIITA and MHC II, even in unstimulated
cells, and has substantial impact on MHC II cell surface expression
in each of the MDA MB 435 variants. These observations suggest
EZH2 is the pivotal regulator of CIITApIV silencing which is in
agreement with our previous observations [29] and implicate
EZH2 as a candidate target for use in activating immune
responses. We further provide novel evidence that EZH2
contributes critical regulatory marks specifically to the silencing
of CIITA transcription and to the regulation of MHC II
expression in MDA MB 435 breast cancer cell variants, indicating
EZH2 may play a role in promoting tumor growth through
immunoevasion in the presence of inflammatory cytokine.
Materials and Methods
Cells
435-Lung 2 and 435-Brain 1 variants of the estrogen
independent MDA MB 435 human breast cancer cell line were
provided by Dr. Janet Price [42]. These cell lines were sent
without identifiers with a Materials Transfer Agreement (MTA)
(M.D. Anderson #6077) governing the transfer and use of these
cell lines. Per institutional policy, M.D. Anderson MTA#6077
was reviewed and approved by the M.D. Anderson IRB on March
23, 2009. The IRB determined that the use of these cell lines in
our research project was not human subject’s research. MDA MB
435 variants were maintained using modified Eagle (MEM)
medium (Mediatech Inc., Herndon, VA) supplemented with 5%
fetal bovine serum (FBS) with the exception of 435-Brain 1 which
were supplemented with 10% FBS, 5 mM L-glutamine and 5 mM
penicillin-streptomycin at 37uC with 5% carbon dioxide. MCF
10A (non tumorigenic human epithelial) and HeLa (human
epithelial) cells were purchased from ATCC (Manassas, VA).
MCF 10A cells were maintained in Mammary Epithelial Cell
Basal medium (MEBM) with the following supplements: 0.5 ml
hydrocortisone, bovine pituitary extract (BPE); 2 ml gentamicin
sulfate amphotericin-B (GA-1000); 0.5 ml human recombined
epidermal growth factor in buffered BSA saline solution (rhEGF);
and 0.5 ml human recombinant insulin. HeLa cells were
maintained in high glucose Dulbecco modified Eagle (DMEM)
medium (Mediatech Inc., Herndon, VA) supplemented with 10%
fetal bovine serum (FBS), 5 mM L-glutamine, and 5 mM
penicillin-streptomycin at 37uC with 5% carbon dioxide.
Antibodies
Antibodies recognizing IRF-1 and STAT-1 were from Santa
Cruz (Santa Cruz, CA). Antibodies recognizing histone H3,
acetylated histone H3, histone H4, acetylated histone H4, and
rabbit and mouse immunoglobulin G (IgG) isotype control
antibodies were from Millipore (Lake Placid, NY). Antibodies
recognizing histone 3 (trimethyl K27), histone 3 (acetyl K27),
histone 3 (trimethyl K9), histone 3 (acetyl K18), CBP, and EZH2
antibodies were from Abcam (Cambridge, MA). Antibody
recognizing EZH2 was from Millipore (Lake Placid, NY); antibody
recognizing Tubulin was from Santa Cruz (Santa Cruz, CA); HRP
conjugated mouse antibody was from Promega (Madison, WI);
and HRP conjugated rabbit antibody was from Pierce (Rockland,
IL).
siRNA Constructs and Transient Transfections
Short interfering RNA (siRNA) duplexes predesigned against
human EZH2 (Qiagen) were used for transient knockdown of
EZH2. Cells were transfected with 1 ug of EZH2 specific siRNA
or All Star scrambled sequence control (Qiagen) using RNAiFect
transfection reagent (Qiagen) according to the manufacturer’s
instructions and were treated with IFN-c (500 U/ml) as indicated.
Cells were lysed in NP-40 lysis buffer (1 M Tris pH 8.0, 1 M KCl,
10% NP-40, 0.5 M EDTA, 5 M NaCl, 1 M DTT, dH2O) with
EDTA free protease inhibitor (Roche) and analyzed by western
blot for knockdown efficiency and specificity.
Flow cytometry for MHC II cell surface expression
Cells were plated at a density of 7610
5, stimulated with IFN-c
(500 U/ml) as indicated, and were trypsinized, washed with PBS
and resuspended in 100 ml of incubation buffer (0.5% bovine
serum albumin in PBS). 10 mg Phycoerythrin (PE)-labeled anti-
human HLA-DR (clone L243, Biolegend, San Diego, CA) or PE
mouse IgG2a k isotype control antibody (Biolegend) was added
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Following antibody incubation, cells were washed with PBS and
fixed with 2% paraformaldehyde. MHC II cell surface expression
was measured by FACS-Canto (Becton Dickinson, San Jose, CA)
and analyzed using FlowJo. All samples were analyzed using
10,000 events per sample.
Flow cytometry for surface expression of MHC II with
EZH2 siRNA
Cells were plated at a density of 7610
5, transfected with 1 mg
EZH2 specific or control siRNA (Qiagen), and twenty four hours
post transfection, stimulated with IFN-c (500 U/ml) as indicated.
Following the stimulation cells were trypsinized, washed with PBS
and 10% of the cell volume was lysed with 1% Nonidet P-40 lysis
buffer and was analyzed by western blot for knockdown efficiency
and specificity. The remaining cell volume was resuspended in
100 ml of incubation buffer and labeled as above.
RNA Expression
Cells were plated at a density of 8610
5 cells and were stimulated
as indicated with IFN-c (500 U/ml). Cells were harvested and
were subjected to RNA extraction with 1 ml of Trizol reagent
(Invitrogen) as previously described [28,43]. An Omniscript
Reverse Transcription Kit (Qiagen) was used to generate cDNA
from extracted RNA. Isolated DNA was analyzed by Q-PCR on
an ABI prism 7900 (Applied Biosystems) using primers and probes
for CIITApIII [44], CIITApIV, HLA-DRA, and GAPDH [28,43].
Primer sequences for EZH2 were as follows: EZH2 sense
TTCATGCAACACCCAACACT, EZH2 antisene GAGAG-
CAGCAGCAAACTCCT, and EZH2 probe FAM-TTACCAG-
CATTTGGAGGGAG-TAMRA. Values generated from Q-PCR
reactions were calculated on the basis of standard curves
generated.
RNA expression in siRNA treated cells
Cells were plated at a density of 8610
5 cells, transfected with
EZH2 specific or control siRNA, and twenty four hours later were
stimulated as indicated with IFN-c (500 U/ml). Cells were
harvested and 10% of the cell volume was lysed with 1% Nonidet
P-40 lysis buffer and subjected SDS PAGE. RNA was extracted
and analyzed from the remaining fraction of cell volume as above.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as previously described
[27,28,43,45]. Briefly, cells were plated at a cell density of
3610
6, stimulated with IFN-c as indicated (500 U/ml), and were
crosslinked with 1% formaldehyde for 10 minutes at room
temperature. Crosslinking was stopped by the addition of
0.125 M glycine for five minutes at room temperature. Cells were
lysed in SDS lysis buffer and were sonicated at constant pulse to
generate an average of 500–750 bp sheared DNA. Sonicated
lysates were precleared with salmon-sperm coated agarose beads
(Upstate) and half of the lysate was immunoprecipitated with 5 mg
of indicated antibody overnight at 4uC. The remaining half of the
lysate was immunoprecipitated with isotype control antibody
(Upstate). Following a two hour immunoprecipitation with 50 mlo f
salmon-sperm coated agarose beads, samples were washed for
3 minutes at 4uC with each of the following buffers: low salt buffer,
high salt buffer, LiCl, and 16TE and were eluted with SDS
elution buffer [45]. Following elution, cross-links were reversed
overnight with 5 M NaCl at 65uC and immunoprecipitated DNA
was isolated using phenol:chloroform:isopropanol mix (Invitrogen)
as per the manufacturer’s instructions. Isolated DNA was analyzed
by Q-PCR using previously published primers spanning the W-X-
Y box of the HLA-DRA promoter and the IRF-E-GAS box of
CIITApIV [27,28,43]. Values generated from Q-PCR reactions
were calculated based on standard curves generated.
Dual crosslinking Chromatin Immunoprecipitation
(dChIP) Assay
Cells were plated at a density of 2.5610
6 cells and were
stimulated as indicated with 500 U/ml IFN-c. Cells were
harvested and washed with PBS, resuspended in 10 ml of PBS
(pH 8.0) containing 1 mM MgCl2 and 1 mM of Disuccinimidyl
Glutarate (DSG) and were incubated at room temperature for
45 minutes as described above [29,45]. Following crosslinking,
0.1 mM Tris pH 7.4 was added for five minutes at room
temperature to block further cross-linking. Cells were washed in
PBS, resuspended in 10 ml of PBS, and formaldehyde cross-
linking was performed as above.
Chromatin Immunoprecipitation with siRNA
ChIP siRNA assays were performed as previously described
[27,28]. Briefly, cells were plated at a density of 8610
5, transfected
with 1 mg EZH2 specific or control siRNA (Qiagen), and
stimulated as indicated with IFN-c (500 U/ml). 10% of the cell
volume was lysed with 1% Nonidet P-40 lysis buffer and was
analyzed by western blot for knockdown efficiency and specificity.
The remaining cell volume was crosslinked, lysed in SDS lysis
buffer, and subjected to sonication and ChIP assay as above.
DNA methylation analysis
MDA MB 435 breast cancer cells or HeLa cells were plated at a
density of 7610
5, trypsinized, washed with PBS and re-suspended
in 5 mL of PBS. Bisulfite treatment of DNA was performed using
the EZ DNA methylation kit (Zymo Research Orange, CA)
according to the manufacturer’s instructions. Hot start touchdown
PCR was performed in 16PCR buffer, 0.25 mM dNTP, 0.5 mM
forward and reverse primer, and 1.0 U Taq polymerase. Primers
specific for CIITApIV CpG island region 2 [46] were used to
amplify the desired segment and the PCR product was run on
1.5% agarose gel, gel extracted, and sequenced.
Results
Differential expression of MHC II by high and low
metastatic variants of MDA MB 435 human breast
carcinoma correlates with decreased expression of HLA-
DRA mRNA
Flow cytometry was used to determine cell surface expression of
MHC II (versus mouse IgG2a k isotype control, Fig. S1A) in
unstained cells (data not shown), in three variants of MDA MB
435 human breast cancer cells, in HeLa cells, and in immortalized,
but non-tumorigenic, epithelial breast MCF 10A cells in response
to IFN-c stimulation (Fig. 1A). Results shown are the percent of
MHC II positive events. Following 24 hours of IFN-c stimulation,
average of 35% of HeLa cells were positive for surface expression
of MHC II, and average of 40% of MCF 10A cells were MHC II
positive. Following 24 hours of IFN-c stimulation, on average
28% of MDA MB 435 cells, 22% of 435-Brain 1, and 16% of435-
Lung 2 cells were positive for MHC II cell surface expression.
Following 48 and 72 hours of cytokine stimulation, MDA MB 435
variants were, on average, 40% positive for cell surface MHC II,
while HeLa and MCF 10A cells were nearly 100% MHC II
positive. HLA-DRA mRNA levels in MDA MB 435 cells (Fig. 1B)
demonstrate a significant 100 fold reduction in HLA-DRA message
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each of the MDA 435 cell variants (Fig. 1B). HLA-DRA mRNA
levels were normalized to GAPDH mRNA which remained
constant.
Histone H3 and histone H4 are acetylated at the
activated HLA-DRA promoter in MDA MB 435 cell variants
Transcription occurs within the highly ordered context of
chromatin and an open chromatin structure is required for
transcription initiation. To determine the availability of HLA-DRA,
Figure 1. MHC II cell surface expression (A) and mRNA expression (B–C) is decreased in MDA MB 435 cells. (A) Cell surface expression of
MHC II on MDA MB 435 variants, HeLa cells, and non metastatic breast MCF 10A cells. Cells were stimulated with IFN-c as indicated, trypsinized,
washed, and incubated with PE-labeled anti-human HLA-DRA antibody. Following antibody incubation, cells were fixed and PE cell surface staining
was measured by FACS-Canto and analyzed using Flow Jo software. Results shown are the percent of MHC II positive events of four independent
experiments. (B) Reduced expression of endogenous HLA-DRA mRNA in MDA MB 435 breast cancer cells compared to HeLa cells. Cells were left
unstimulated or were stimulated with IFN-c as indicated and levels of mRNA were measured by Q-PCR and were normalized to GAPDH mRNA. Results
shown represent the mean 6 SD of four independent experiments. (C–D) Levels of acetylated H3 (C) and acetylated H4 (D) at the HLA-DRA promoter.
ChIP assays were carried out in cells stimulated as indicated with IFN-c. Lysates were immunoprecipitated with control antibody, with antibody to
acetylated H3 (C) or with antibody to acetylated H4 (D) and associated DNA was isolated and analyzed via real time Q-using primers spanning the W-
X-Y box of the HLA-DRA promoter. Values for acetylated H3 (C) and acetylated H4 (D) IPs represent mean 6 SEM of three independent experiments.
Control IP values for (C) and (D) were 0.460.1*** P,0.0005, **P,0.005, *P,0.05.
doi:10.1371/journal.pone.0036013.g001
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MB 435 cell variants. Cells were left untreated or were stimulated
with IFN-c as indicated and were subjected to chromatin
immunoprecipitation (ChIP) analyses. Lysates were immunopre-
cipitated with antibody against acetylated H3 (Fig. 1C) or
acetylated H4 (Fig. 1D) and were analyzed via Q- PCR with
primers and probe spanning the HLA-DRA promoter. Following
IFN-c stimulation, levels of acetylated H3 and H4 increase in all
MDA MB 435 variants. However levels of acetylated H3 (Fig. 1C)
and acetylated H4 (Fig. 1D) were significantly reduced in IFN-c
stimulated 435-Lung 2 cells when compared to the heterogeneous
MDA MB 435 parental cell line. As previous studies demonstrate
histone H3 lysine 18 (K18) is strongly acetylated at activated HLA-
DRA [47], ChIP experiments were next performed to determine
levels of HLA-DRA acetylation on H3K18 in MDA MB 435
variants. Cells were stimulated with IFN-c as indicated, were
subjected to ChIP analyses with antibody against acetylated
H3K18, and were analyzed by Q-PCR with primers and probe
spanning the HLA-DRA promoter. Levels of H3K18 acetylation
were elevated with cytokine stimulation and no significant changes
in H3K18 acetylation were observed between variants of MDA
MB 435 cells or in comparison to HeLa cells (Fig. S2A). The
histone acetyltransferase (HAT) CREB binding protein (CBP/
p300) interacts with CIITA [16,48] and is known to acetylate both
H3 and H4 at the HLA-DRA promoter and to enhance binding of
CIITA to the MHC II enhanceosome complex [49]. ChIP
analyses indicate recruitment of CBP to HLA-DRA upon cytokine
stimulation in each of the MDA MB 435 variants and in HeLa
cells (Fig. S2B). Together, these data indicate that loss of inducible
HLA-DRA promoter acetylation in MDA MB 435 cells is not
responsible for the inability of these cells to inducibly express
maximum levels of cells surface MHC II.
Silencing modifications decrease at the activated HLA-
DRA promoter in MDA MB 435 cell variants
In order to determine patterns of histone trimethylation of
histone H3 lysine 9 (H3K9me3) and of histone H3 lysine 27
(H3K27me3) at the HLA-DRA promoter, HeLa cells and MDA
MB 435 cell variants were stimulated with IFN-c and ChIP
analysis was performed. Levels of H3K9me3 and H3K27me3
were significantly reduced at the HLA-DRA promoter within 4 hrs
of cytokine stimulation and were eliminated 18 hrs post IFN-c
stimulation in each of the three variants of MDA MB 435 cells and
in HeLa cells (Fig. S2C–D). Together these data indicate sustained
histone methylation at the HLA-DRA promoter is not responsible
for suppressed cell surface expression of MHC II in cytokine
stimulated MDA MB 435 cell variants.
Acetylation of H3K27 (H3K27ac) is catalyzed by CBP and is
associated with multiple active mammalian genes. To determine
levels of H3K27ac on the HLA-DRA promoter in MDA MB 435
cells and in HeLa cells, we performed ChIP assays with antibodies
recognizing H3K27ac. Levels of H3K27ac on HLA-DRA increase
significantly with cytokine stimulation in each of the three variants
of MDA MB 435 cells with levels comparable to H3K27ac in
HeLa cells (Fig. S2E); further indication the HLA-DRA promoter is
opened and available upon IFN-c stimulation.
Despite suppression of CIITA mRNA in MDA MB 435
variants, histone H3 and histone H4 are inducibly
acetylated at CIITA pIV
CIITA expression and subsequent binding to the HLA-DRA
promoter is essential for transcriptional activation of HLA-DRA
genes. Four different promoters have been described to regulate
transcription of CIITA, each being characterized by a different
first exon [25]. As promoters III and IV both drive CIITA
expression following IFN-c stimulation, we determined the relative
expression of CIITA isoform III and isoform IV mRNA in
stimulated HeLa cells and in each of the three MDA MB 435
variants. Cells were stimulated with IFN-c as indicated and
analyzed via Q-PCR using primers specific for CIITApIII (Fig. 2A)
and for CIITApIV (Fig. 2B). In comparison to significant increases
in CIITApIII and pIV mRNA expression in HeLa cells in
response to IFN-c stimulation, both CIITApIII and pIV
expression levels are suppressed in each variant of MDA MB
435 cells (Fig. 2A–B).
Our observations of significant decreases in CIITApIV
transcripts between MDA MB 435 variants (Fig. 2B) led us to
next focus our analysis on the levels of global histone acetylation at
CIITApIV using ChIP assays and antibodies against acetylated
H3 and acetylated H4. Q-PCR analysis indicated that levels of
acetylated H3 (Fig. 2C) and of acetylated histone H4 (Fig. 2D) at
CIITApIV decrease between MDA MB 435 variants upon
stimulation with IFN-c. Additionally, levels of CIITApIV H3
and H4 acetylation in HeLa cells are significantly more robust
than those in the MDA MB 435 cell variants (Fig. 2C–D). To
analyze levels of acetylated H3K18 and association of the HAT
CBP at CIITApIV in the MDA MB 435 variants, cells were left
untreated or were stimulated with IFN-c as indicated, subjected to
immunoprecipitation with antibody to acetylated H3K18 (Fig. 3A)
or CBP (Fig. 3B), and were analyzed via Q-PCR with primers and
probes spanning the CIITApIV proximal promoter. Total levels of
acetylated H3K18 and CBP at CIITApIV in 435-Brain 1 and
435-Lung2 cells significantly decreased upon cytokine stimulation
in comparison with the heterogeneous parental MDA MB 435
cells. Levels of inducible H3K18 acetylation and levels of CBP
binding at CIITApIV were both lower in each of the MDA MB
435 variants in comparison to HeLa cells (Fig. 3A–B). As total
levels of CBP remain unchanged between MDA MB 435 variants
(Fig. S3C), CBP binding, not expression, likely accounts for
decreased histone acetylation within the variants.
CIITApIV is specifically and inducibly hypermethylated at
CIITApIV in MDA MB 435 cell variants
To determine CIITApIV levels of H3 lysine 9 and lysine 27
methylation and levels of lysine 27 acetylation in MDA MB 435
cell variants, ChIP experiments were performed using antibodies
against H3K9me3, H3K27me3, and H3K27ac. Q-PCR analysis
indicated elevated basal levels of H3K9me3 at CIITApIV that
significantly decrease upon stimulation with IFN-c in the MDA
MB 435 variants and in HeLa cells (Fig. 3C). Basal levels of
CIITApIV H3K27me3 were observed in MDA MB 435 cell
variants; however, following IFN-c stimulation, CIITApIV levels
of H3K27me3 significantly, and unexpectedly, increased correl-
ative with increasing metastatic potential of MDA MB 435 cell
variants (Fig. 3D). The inducible hypermethylation of lysine 27
observed at CIITApIV is cell line specific as ChIP assays
performed in HeLa cells demonstrate an opposite trend where
elevated levels of CIITApIV H3K27me3 in unstimulated cells
significantly decrease upon IFN-c stimulation (Fig. 3D). We
further observed that maximum levels of cytokine induced
H3K27ac decrease between the MDA MB 435 variants and
when these variants are compared to HeLa (Fig. 3E).
To determine if epigenetic alterations at CIITApIV are
sequence specific, ChIP assays were performed to detect levels of
H3K27me3, H3K9me3, H3K27ac, and H3K18ac at the GAPDH
promoter (Fig. S1B). Low levels of methylation and high levels of
acetylation were observed at the GAPDH promoter that were
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different between MDA MB 435 cell variants. Gains in
H3K27methylation at CIITApIV in the MDA MB 435 cell
variants are not indicative of increases in histone H3 or histone H4
as ChIP assays demonstrate no significant changes in the level of
H3 (Fig. 3A) or H4 (supplementary Fig. S3B) in any of the MDA
MB 435 cell variants. In sum, these data indicate elevated levels of
inducible H3K27me3 at CIITApIV are likely responsible for the
increasingly suppressed levels of CIITA mRNA in MDA MB 435
cell variants.
IFN-c inducible recruitment of STAT-1 and IRF-1 to
CIITApIV is diminished in MDA MB 435 cell variants
The transcription factors STAT-1 and IRF-1 are both required
for CIITApIV transcription in response to IFN-c stimulation [25].
To determine if the lack of CIITA mRNA in MDA MB 435 cell
variants was due to reduced expression of STAT-1 and IRF-1,
Western blot analyses were performed. Levels of STAT-1 and
IRF-1 remain consistent in the MDA MB 435 variants (Fig. S3C),
indicating both STAT-1 and IRF-1 are expressed and available
for CIITApIV binding. Levels of phosphorylated STAT-1
(pSTAT-1) are similarly induced in the MDA MB 435 variants,
indicating activation of the JAK-STAT pathway is unaffected (Fig.
S3C).
An open chromatin confirmation is required for the initiation of
transcription. Data in Fig. 3 indicate that CIITApIV is
hypermethylated and in a closed confirmation in cytokine
stimulated MDA MB 435 cell variants. To confirm the closed
status of chromatin at CIITApIV, promoter recruitment of STAT-
1 and IRF-1 was analyzed by ChIP assays in MDA MB 435
variants and in HeLa cells. Cells were stimulated with IFN-c as
indicated and were subjected to immunoprecipitation with
antibody recognizing STAT-1 or IRF-1. ChIP data indicate low
level recruitment of STAT-1 and IRF-1 to CIITApIV in each of
the MDA MB 435 variants with minimal increases in binding
following IFN-c stimulation (Fig. 4A–B). Levels of STAT-1 and
IRF-1 binding to CIITApIV were significantly diminished in
comparison to STAT-1 and IRF-1 binding to CIITApIV in HeLa
cells (Fig. 4A–B).
Binding of the histone methyltransferase EZH2 to
CIITApIV is significantly and specifically increased in MDA
MB 435 cell variants
Histone methyltransferases (HMTs) are chromatin remodeling
enzymes that add one, two, or three methyl groups to lysine
residues on histones [50]. We have recently demonstrated the
HMT enhancer of zeste homolog 2 (EZH2), a known regulator
H3K9me3 and H3K27me3 [36,51], to be a critical regulator of
IFN-c inducible transcription from CIITApIV [29]. Initial
Figure 2. Decreased levels of CIITA isoform III and isoform IV mRNA correlates with low levels of acetylation. (A–B) HeLa and MDA MB
435, 435-Brain 1, and 435-Lung 2 cells were treated as indicated with IFN-c. Levels of CIITApIII mRNA (A) and CIITApIV mRNA (B) were measured by Q-
PCR. Results shown represent the mean 6 SD of four independent experiments. (C–D) Levels of acetylated H3 (C) and acetylated H4 (D) at CIITApIV in
MDA MB 435 and HeLa cells. ChIP assays were carried out in cells stimulated as indicated with IFN-c. Lysates were IP with control antibody, with
antibody to acetylated H3, (C) or with antibody to acetylated H4 (D) and associated DNA was isolated and analyzed via Q-PCR using primers spanning
the IRF-E-GAS box of CIITApIV. Values for control IPs and acetylated H3 (C) and acetylated H4 (D) IPs represent the mean 6 SEM of three independent
experiments. Control IP values for (C) and (D) were 0.660.5 *** P,0.0005, **P,0.005, *P,0.05.
doi:10.1371/journal.pone.0036013.g002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36013Figure 3. Decreased levels of CIITApIV H3K18ac, H3K27ac and CBP correlate with significantly elevated levels of H3K27me3 in
metastatic breast cancer cells. (A–E) Levels of acetylated H3K18, CBP, H3K9me3, H3K27ac, and H3K27me3 at CIITApIV. ChIP assays were carried
out in MDA MB 435, 435-Brain 1, 435-Lung 2, and HeLa cells stimulated as indicated with IFN-c. Lysates were IP with control antibody or antibody to
indicated proteins and associated DNA was isolated and analyzed as above. Values shown represent mean 6 SEM of three to five independent
experiments. Control IP values for (A–E) were 1.360.7 ***P,0.0005, **P,0.005.
doi:10.1371/journal.pone.0036013.g003
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expresses similar levels of EZH2 mRNA (Fig. 5A) and EZH2
protein (Fig. S3E). To determine if EZH2 aberrantly binds
CIITApIV in the MDA MB 435 variants and HeLa cells, ChIP
assays were performed. Cells were stimulated with IFN-c as
indicated and were subjected to immunoprecipitation with
antibody against EZH2. Chromatin immunoprecipitation showed
comparable EZH2 binding to HLA-DRA (Fig. 5B) and to
CIITApIV (Fig. 5C) in unstimulated cells (note Y axis differences).
Four hours post cytokine stimulation, EZH2 occupancy decreases
at HLA-DRA promoter and reaches baseline binding 18 hours
following cytokine stimulation (Fig. 5B). Striking differences in
EZH2 binding patterns were observed at CIITApIV in the MDA
MB 435 variants. In unstimulated cells, EZH2 binds to CIITApIV
at levels similar to that of HLA-DRA. However, upon cytokine
stimulation, EZH2 binding increases in each variant of MDA MB
435 cells, at both four and 18 hours post IFN-c stimulation
(Fig. 5C). By comparison, in HeLa cells, patterns of EZH2 binding
to CIITApIV (Fig. 5C) are similar to binding of EZH2 at HLA-
DRA (Fig. 5B).
Analysis of CIITApIV CpG islands indicates no
differences in DNA methylation within the variants of the
MDA MB 435 cells. In trophoblasts, expression of CIITA is
blocked by CIITApIV start site proximal DNA methylation [52]
and DNA methylation at regions 2 and 3 of the 59 CIITApIV
CpG island has been detected in colorectal and gastric cancers
which lack CIITA expression [46]. Previous studies indicate 435-
Lung2 cells treated with 5-aza CR, an inhibitor of DNA
methylation, restore expression of CIITA mRNA and MHC II
protein synthesis [42]. To more fully address roles for promoter
proximal DNA methylation in suppression of CIITApIV in MDA
MB 435 variants, we used four primer sets and bisulfate restriction
analysis to analyze DNA methylation levels at regions 2 and 3 of
the 59 CIITApIV CpG island in each of the MDA MB 435
variants (Fig. 5D) [46]. No differences in methylated (boxed
regions) or unmethylated (arrowed regions) DNA were detected
between variants of MDA MB 435 cells, suggesting reduced
CIITA expression in the variants of MDA MB 435 are not due to
changes in DNA methylation.
Knockdown of EZH2 significantly reduces H3K27me3 at
CIITApIV in the MDA MB 435 variants
To further investigate roles for EZH2 in the suppression of
CIITApIV in the MDA MB 435 variants, we utilized siRNA
duplexes to specifically knock down expression of EZH2 and
performed ChIP assays to detect levels of H3K27me3 at
CIITApIV. siRNA mediated knockdown of EZH2 resulted in
specific decreases in EZH2 protein expression (Fig. 6A). To further
determine efficiency of the siRNA duplexes, EZH2 mRNA levels
were tested in each of the MDA MB 435 variants (Fig. 6B). Cells
treated with EZH2 specific siRNA (white bars) showed significant
reductions in EZH2 mRNA levels when compared to cells treated
with control siRNA (black bars). To determine levels of
H3K27me3 at CIITApIV in the EZH2 siRNA treated MDA
MB 435 cell variants, ChIP assays were performed. In cells treated
with control siRNA, levels of H3K27me3 increase at CIITApIV
upon IFN-c stimulation (Fig.6C, black bars). However, when
specific siRNA was used to knockdown EZH2, significant
decreases in CIITApIV H3K27me3 were observed in each of
Figure 4. Decreased recruitment of STAT-1 and IRF-1 to CIITApIV in metastatic breast cancer cells. (A–B) ChIP assays were carried out in
MDA MB 435 variants and HeLa cells stimulated as indicated with IFN-c. Lysates were IP with control antibody, with antibody to STAT-1 (A), or with
antibody to IRF-1 (B), and associated DNA was analyzed as above. IP values shown are presented as increases in CIITApIV promoter DNA relative to
unstimulated STAT-1 (A) and IRF-1 (B) IP samples. Values for control IPs, STAT-1 IP’s, and IRF-1 IPs represent mean 6 SEM of three independent
experiments. Control IP values for (A) and (B) were 0.260.3.
doi:10.1371/journal.pone.0036013.g004
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36013Figure 5. IFN-c stimulation results in specific and significantly increased binding of EZH2 to CIITApIV in MDA MB 435 cells. (A) EZH2
mRNA expression. MDA MB 435, 435-Brain 1, 435-Lung 2, and HeLa cells were stimulated as indicated with IFN-c. Cell lysates were analyzed for levels
of EZH2 mRNA as above. Q-PCR was performed in triplicate and results represent the mean 6 SD of three independent experiments. (B–C) Levels of
EZH2 at HLA-DRA (B) and CIITApIV (C) promoters post cytokine stimulation. Double crosslinking ChIP assays were carried out in cells stimulated as
indicated with IFN-c. Lysates were IP with control antibody or with antibody to EZH2 and associated DNA was isolated and analyzed via Q-PCR using
primers spanning the W-X-Y box of HLA-DRA (B) and using primers spanning the IRF-E-GAS box of CIITApIV (C). Values for control IPs and for and
EZH2 IPs represent mean 6 SEM of three independent experiments. Control IP values for (A) and (B) were 2.160.5 ***P,0.0005. (D) DNA methylation
analyses of CIITApIV. Sequence analysis of CIITApIV region 2 of MDA MB 435 cells and HeLa cells indicates no differences in CpG island methylation.
Primers spanning region 2 of CIITApIV were used to amplify DNA and purified PCR product was sequenced and aligned with cells lines. Arrows
indicate unmethylated CpG sites. Boxes indicate methylated CpG sites conserved between MDA MB 435 cells and HeLa cells.
doi:10.1371/journal.pone.0036013.g005
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bars). These data suggest EZH2 is responsible for the elevated
levels of CIITApIV H3K27me3 in the variants of MDA MB 435.
Knocking down EZH2 restores suppressed levels of
CIITApIV and HLA-DRA mRNA as well as cell surface
expression of MHC II in each of the variants of MDA MB
435
To determine if decreased expression of EZH2 and a resulting
decrease in CIITApIV H3K27me3 can reconstitute CIITA and
HLA-DRA gene expression in the MDA MB 435 variants, mRNA
experiments were performed. Cells were transfected with EZH2
specific or control siRNA and were stimulated with IFN-c as
indicated. Following stimulation cells were lysed and CIITApIV
and HLA-DRA mRNA levels were quantified via Q-PCR. Both
CIITA and HLA-DRA mRNA levels are significantly elevated in
cells treated with EZH2 specific siRNA (Fig. 7A, white bars) when
compared to cells treated with control siRNA (Fig. 7A, black bars).
Significantly, decreased expression of EZH2 increases both CIITA
and HLA-DRA message levels in each of the MDA MB 435
variants, even in the absence of IFN-c stimulation. We further
investigated roles for EZH2 in restoring expression of CIITApIII
by using EZH2 specific siRNA to knockdown EZH2 expression,
followed by analysis of CIITApIII mRNA. Both EZH2 and
control siRNA treated cells demonstrated similar levels of
CIITApIII mRNA with and without IFN-c stimulation, indicating
roles for EZH2 in suppressing CIITA expression are promoter
specific ( Fig. 7B). Flow cytometry was used to determine if MDA
MB 435 variants expressed increased cell surface MHC II in
response to IFN-c stimulation when treated with EZH2 specific
siRNA. Levels of MHC II expression in the MDA MB 435
parental cells line, the 435-Brain1 variant, and the 435-Lung2
variant, were all enhanced in EZH2 siRNA treated samples when
compared to cells transfected with control siRNA (Fig. S4).
Together, these studies suggest hypermethylation of histone tails
silences CIITApIV gene expression in MDA MB 435 variants.
Discussion
Our study correlates decreased expression of MHC II in breast
cancer cells with epigenetic suppression of CIITApIV by the
histone methyltransferase EZH2. In variants of MDA MB 435
cells, metastatic potential negatively correlates with expression of
MHC II and with active transcription of the MHC II master
regulator, CIITA. We show here that silencing of MHC II
molecules in highly metastatic breast cancer cells is associated with
distinct epigenetic modifications targeted specifically to the
chromatin of CIITApIV. In these cells, transactivation from
CIITApIV is actively suppressed by increased binding of the
histone methyltransferase EZH2 and by increased H3K27me3,
even in the presence of the inflammatory cytokine IFN-c. These
findings are supported by our recent observation that EZH2 is a
master regulator of CIITA and indicate promoter specific roles for
EZH2 [29].
Tumors which best avoid immune recognition are an increased
risk for metastasis and tumor related mortality. Tumors of the
breast are no exception to this rule with the most common sites for
breast cancer metastasis being the lung, liver, bone, brain, and
auxiliary lymph nodes [53]. To achieve metastatic ability, tumor
cells specifically alter immune gene expression patterns in order to
escape host immune surveillance. Multiple tumor types, including
colorectal and gastric tumors [46], trophoblastic tumors [52], T
cell leukemias, and developmental tumors [54], accomplish
specific decreases in MHC II expression by silencing IFN-c
inducible CIITApIV [55]. While decreased MHC cell surface
expression is considered to be an important factor in predicting
tumor metastasis and patient prognosis, the mechanism of MHC
II suppression has remained unknown [56,57,58]. Decreased
expression of MHC II has been observed in metastatic breast
tumors and in multiple breast cancer cell lines, indicating that
suppression of MHC II may have causative, rather than
correlative, relationships with immune evasion and with metastatic
potential in breast tumors [39,59,60,61,62,63]. We provide
evidence that expression of MHC II genes correlates with the
ability of breast cancer cells to metastasize. The more metastatic
the MDA breast cancer cell line, the less MHC II is induced in the
presence of IFN-c stimulation. In these cell lines, decreases in IFN-
c inducible transcript levels of the MHC II master regulator
CIITA are specifically associated with the silencing modification
H3K27me3 at CIITApIV. Notably, acetylation levels were not
significantly impacted in poorly or highly metastatic MDA
variants, suggesting the dominance of H3K27me3 in the IFN-c
induced chromatin dynamics at CIITApIV. The ramifications of
our study to tumors of the breast are clear and support previous
findings regarding suppression of CIITA in breast cancer [42]:
breast tumors may increase metastatic properties by epigenetically
targeting CIITApIV resulting in suppression of cell surface
expression of MHC II. As MHC cell surface expression is
indispensable for T cell interaction and the presentation of tumor
derived peptides to helper T cells [8,9], breast cancer cells likely
down regulate MHC II genes to avoid immune recognition.
Silencing of MHC II molecules in metastatic cell lines is associated
with dysregulated epigenetic modifications at the proximal
promoter of CIITApIV. Significant decreases in CIITA transcript
levels, even in cells stimulated with IFN-c, resulted in both
decreased HLA-DRA transcripts and in decreased cell surface
expression of MHC II. Expression of MHC II genes correlates
with metastatic ability of the MDA MB 435 variants as indicated
by baseline expression of MHC II in the highly metastatic 435-
Lung2 variant. The lack of transactivation from CIITApIV is not
due to defective IFN-c signaling as pSTAT-1 levels are unchanged
between the MDA MB 435 variants. The requisite CIITApIV
transcription factors STAT-1 and IRF-1 are expressed in the
MDA MB 435 variants, but exhibit limited capability to bind
CIITApIV, even in the presence of IFN-c stimulation. Decreases
in CIITA transcript levels correlate with elevated H3K27me3 at
CIITApIV, while neither H3K9me3 nor H3 or H4 acetylation
demonstrate significant alterations in the MBD MB 435 variants.
Levels of activating H3K27ac are also significantly decreased at
CIITApIV, and inversely correlate with high levels of H3K27me3.
These observations underline the dominance of H3K27me3 in
regulating the transcriptional status of CIITApIV chromatin.
As the catalytic subunit of PRC2, EZH2 adds three methyl
groups to lysine 27 resulting in chromatin condensation. Converse
to frequent observations of decreased MHC II expression in
tumors are observations of overexpression of EZH2 in diverse
tumors types including prostate, breast and bladder cancers and
links to enhanced tumor cell proliferation [64,65,66]. Elevated
expression of EZH2 correlates with metastatic tumor growth and
with clinically aggressive behaviors in prostate and breast cancer
[67], have been recognized as a negative prognostic marker for a
number of breast and prostate cancer patients [68,69], and are
associated with poor outcomes to tamoxifen therapy in advanced
breast cancer patients [70]. Our observations add to this growing
field by indicating that dysregulated promoter recruitment of
EZH2 to CIITApIV also occurs in MDAMB 435 variants and
further indicates EZH2 as a primary culprit in metastatic tumor
growth. We demonstrate here significant levels of EZH2 and
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been previously characterized as highly metastatic [42]. Most
striking is the novel observation that decreased expression of
EZH2 results in constitutive expression of CIITApIV and HLA-
DRA transcripts in unstimulated tumor cells; these results provide
increased evidence for EZH2 as a target for anti-tumor
immunotherapies and provide additional mechanistic links to
roles for EZH2 in tumor cell metastasis.
Our results support a hypothesis that hypermethylation of
histone tails by EZH2 but not DNA methylation represses
CIITApIV gene expression in metastatic variants of MDA MB
435 cells. It is noteworthy that the master regulator CIITA is in
turn controlled by its own master regulator, EZH2. One possibility
Figure 6. EZH2 knockdown decreases CIITApIV histone H3K27 trimethylation. (A–B) EZH2 knockdown is efficient and specific. MDA MB
435, 435-Brain 1, and 435-Lung 2 cells were transfected with either EZH2 specific siRNA or with control siRNA. 10% of lysates were subjected to
immunoblot (IB) for EZH2 and tubulin. Results reported are representative data from three independent experiments. The remaining lysates were
subjected to EZH2 mRNA isolation and quantitation by Q-PCR. Q-PCR was performed in triplicate and results shown represent the mean 6 SD of
three independent experiments. (C) Levels of trimethylated H3K27 in breast cancer cells. ChIP assays were carried out in MDA MB 435 variants
transfected with either EZH2 siRNA or control siRNA and stimulated as indicated with IFN-c. Lysates were IP with control antibody or with antibody to
H3K27me3 and associated DNA was isolated and analyzed as above via Q-PCR using primers spanning the IRF-E-GAS box of CIITApIV. Values shown
represent mean 6 SEM of three independent experiments. Control IP values were 1.260.6 ***P,0.0005, **P,0.005.
doi:10.1371/journal.pone.0036013.g006
Figure 7. EZH2 knockdown significantly increases mRNA levels of CIITApIV and HLA-DRA but not CIITApIII in MDA-MB 435 variants.
(A–B) MDA MB 435 variants were transfected with either EZH2 specific siRNA or with control siRNA and were stimulated as indicated with IFN-c.
Levels of HLA-DRA mRNA and CIITApIV mRNA (A) and levels of CIITApIII mRNA (B) were measured by Q-PCR and were normalized to levels of GAPDH
mRNA. Q-PCR was performed in triplicate and results shown represent the mean 6 SD of three independent experiments. ***P,0.0005, **P,0.005,
*P,0.05.
doi:10.1371/journal.pone.0036013.g007
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promoter occupancy and IFN-c dependent recruitment of EZH2.
These observations are in agreement with previous findings that
overexpression of CIITA in MDA MB 435 variants blocks lung
metastasis [71], and suggest EZH2 is a pivotal and specific
contributor to CIITApIV silencing. While EZH2 has been
demonstrated to interact with DNA methyltransferases and
EZH2 binding has been shown to be required for DNA
methylation of EZH2 target promoters [72], our data indicate
no differences in the CpG methylation of a previously character-
ized promoter region of CIITApIV. Better understanding of the
mechanisms responsible for decreased expression of MHC II in
metastatic breast cancer cells will enable development of novel
ways of enhancing tumor recognition and eradication by the
immune system.
Supporting Information
Figure S1 Isotype control staining of variants of MDA-
MB 435, HeLa, and MCF 10A, and levels of H3K27me3,
H3K9me3, H3K18ac, and H3K27ac at the GAPDH
proximal promoter, are unaffected by cytokine stimu-
lation in MDA MB 435, 435-Brain 1, and 435-Lung 2
cells. (A) MDA MB 435, 435-Brain 1, 435-Lung 2 cells, HeLa
cells, and MCF 10A cells were stimulated with IFN-c as indicated.
Post stimulation cells were trypsinized, washed, and incubated
with PE-labeled mouse control IgG. Following antibody incuba-
tion, cells were fixed and PE cell surface staining was measured by
FACS-Canto. Results shown are representative of three indepen-
dent experiments. (B) Cells were stimulated as indicated and were
subjected to ChIP assay as above. Lysates were IP with isotype
control antibodies or antibodies against indicated histone modi-
fication; associated DNA was isolated and analyzed via Q-PCR
using primers spanning the GAPDH proximal promoter. Values
shown represent mean 6 SEM of two independent experiments.
Average control IP values were 3506200
(TIF)
Figure S2 IFN-c induced levels of H3K18ac, H3K27ac,
CBP, H3K9me3, and H3K27me3 at the HLA-DRA
promoter in HeLa cells and MDA MB 435 variants. (A–
E) ChIP assays were carried out in HeLa cells, MDA MB 435
breast cancer cells, 435-Brain 1 cells, and 435-Lung2 cells
stimulated as indicated with IFN-c as described above. DNA
was isolated and analyzed via Q-PCR using primers spanning the
W-X-Y box of the HLA-DRA promoter. Values represent mean 6
SEM of two independent experiments for HeLa and four
independent experiments for MDA MB 435 variants. Average
control IP values were 0.960.7
(TIF)
Figure S3 Levels of H3 and H4 remain unchanged in
HeLa cells and in MDA MB 435 variants stimulated with
IFN-c. (A and B) Cells were stimulated as indicated with IFN-c.
Following stimulation lysates were subjected to ChIP analyses and
IP with control antibody or with antibody against histones H3 (A)
or H4 (B). DNA was analyzed via Q-PCR with primers and probes
spanning the CIITApIV IRF-E-GAS. IP values shown represent
mean 6 SEM of two independent experiments. Control IP values
for (A) and (B) were 1.860.7 (C) IRF-1, STAT-1, pSTAT-1,
EZH2 and CBP protein expression. MDA MB 435 variants were
stimulated with IFN-c, harvested and subjected to Western Blot
analysis of indicated proteins. Results shown are representative of
three independent experiments.
(TIF)
Figure S4 Cell surface expression of MHC II in MDA
MB 435, 435-Brain1, and 435-Lung2 cells treated with
EZH2 siRNA. Cells were plated, treated with control siRNA or
with EZH2 specific siRNA, and were stimulated with IFN-c for
36 hours. Following stimulation, cells were trypsinized, washed,
and incubated with PE-labeled anti-human HLA-DRA antibody.
Following antibody incubation, cells were fixed and PE cell surface
staining was measured by FACS-Canto. Results shown are
representative of three independent experiments.
(TIF)
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